Mindpeak Secures First Patent for Advanced AI in Digital Pathology

Mindpeak is proud to announce its new collaboration with Techcyte, a leading provider of AI-driven digital diagnostics, by joining the Techcyte Fusion™ Partner Program. This partnership brings together two pioneers in artificial intelligence for pathology, united by a mission to enhance diagnostic accuracy, efficiency, and reproducibility in cancer research and diagnostics.

Supporting Labs with Seamless AI Integration

Mindpeak’s suite of AI tools—including Research Use Only (RUO) algorithms for breast, prostate, and gastric cancer, alongside advanced IHC marker analysis—will now be available through the Techcyte Fusion™ platform. By integrating Mindpeak’s robust, explainable AI models, labs worldwide can benefit from interoperable solutions that fit naturally into existing workflows, supporting reproducible research and streamlined daily operations.

“We built Mindpeak to support pathologists with reliable, explainable AI that integrates effortlessly into daily routines,” said Felix Faber, Founder and CEO of Mindpeak. “Partnering with Techcyte allows us to reach more labs with a shared commitment to transforming cancer diagnostics through high-quality, scalable solutions.”

A Shared Vision for the Future of Pathology

The partnership underscores a shared vision: driving the future of digital pathology through validated, workflow-based AI. As labs face growing complexity and demand, collaborations like this will play a critical role in enabling faster, more precise insights and ultimately improving patient care.

Learn More
https://www.einpresswire.com/article/830144303/mindpeak-joins-techcyte-fusion-partner-program-to-accelerate-ai-powered-digital-pathology

‍

‍

We’re beyond excited to partner with AstraZeneca to evaluate and deploy our AI-powered solution for early breast cancer detection in multiple centers around the globe.

The collaboration investigates the role of AI in enhancing diagnostic accuracy, optimizing pathology workflows, and supporting pathologists in detecting invasive breast cancer and Ductal Carcinoma in Situ (DCIS) more resource-efficiently and at an earlier stage.

Breast cancer is the most common cancer among women worldwide, with over 2.3 million new cases annually. Early and accurate diagnosis is critical, yet many healthcare systems struggle with pathologist shortages and increasing case volumes —  to delays in detection and treatment.

By integrating our AI products into digital pathology workflows, we strive to accelerate diagnoses, boost efficiency, and ultimately improve patient outcomes.This is a major milestone in the future of AI-driven digital pathology —  and we’re just getting started!

‍

Read the full article here: https://lnkd.in/eNSA2ZHg

Mindpeak GmbH and Lumea announce a strategic partnership to advance AI in pathology!

This partnership brings Mindpeak’s AI applications to Lumea’s BxLink platform, offering users broader access to state-of-the-art tools for improved diagnostic precision and enhanced lab efficiency.

Read more about this exciting partnership: https://lnkd.in/gnWv9pyf